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Abstract
Background
Interferon-beta (IFN-beta) is a commonly used treatment for multiple sclerosis (MS). Current
guidelines recommend cessation of treatment during pregnancy, however the results of
past studies on the safety of prenatal exposure to IFN-beta have been conflicting. A large
scale study of a population of MS women is therefore warranted.
Objectives
To assess whether, among those born to women with MS, infants prenatally exposed to
IFN-beta show evidence of smaller size at birth relative to infants which were not prenatally
exposed to any MS disease modifying drugs.
Methods
Swedish and Finnish register data was used. Births to women with MS in Sweden and Fin-
land between 2005–2014 for which a birth measurement for weight, height, and head cir-
cumference was available were included. The exposure window was from 6 months prior to
LMP to the end of pregnancy.
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Results
In Sweden, 411 pregnancies were identified as exposed to IFN-beta during the exposure
window, and 835 pregnancies were counted as unexposed to any MS DMD. The corre-
sponding numbers for Finland were 232 and 331 respectively. Infants prenatally exposed to
interferon-beta were on average 28 grams heavier (p = 0.17), 0.01 cm longer (p = 0.95), and
had head circumferences 0.14 cm larger (p = 0.13) in Sweden. In Finland, infants were 50
grams lighter (p = 0.27), 0.02 cm shorter (p = 0.92) and had head circumferences 0.22 cm
smaller (p = 0.15) relative to those unexposed.
Conclusions
This study provides evidence that exposure to IFN-beta during pregnancy does not influ-
ence birth weight, length, or head circumference.
Introduction
Multiple sclerosis (MS) is an immune mediated disease causing demyelination and axonal loss
in the central nervous system (CNS) [1]. Women with MS often cease treatment during preg-
nancy, in part due to immunological adaptations during pregnancy including suppression of
T-cell activity[2], which occur to allow foetal growth without the foetus being recognised as a
foreign agent by the immune system, often reducing symptoms[3]. Interferon beta (IFN-beta)
is a commonly used disease modifying treatment for MS, with current guidelines recommend-
ing cessation during pregnancy. Pregnant women are often excluded from clinical trials,
meaning the effects of prenatal exposure are not known, resulting in a preference to cease
treatment. If the pregnancy is planned, decisions need to be made as to whether treatment
should be continued. However not all pregnancies are planned and some women will conceive
whilst on treatment, making foetal exposure to IFN-beta inevitable in some instances. The pos-
sible effects of this are not known with certainty. Results from smaller scale studies generally
show no adverse pregnancy outcomes for mothers exposed to IFN-beta during pregnanc[4–8].
However, some studies have concluded that exposure could potentially be detrimental, making
the benefit–risk assessment for mother and child and therefore the decision to continue or dis-
continue treatment after conception difficult[9]. Given conflicting outcomes in past research
[4–9], an investigation into potential adverse pregnancy outcomes related to foetal exposure to
IFN-beta using larger populations of women with MS rather than smaller samples is therefore
warranted.
This study utilized administrative data from Sweden and Finland to compare birth mea-
surements (birth weight, height, and head circumference) of infants of women with MS
exposed to IFN-beta, and infants of women with MS unexposed to MS disease modifying
drugs (DMD).
Methods
Study population and data sources
Pregnancies resulting in a live birth to women with a diagnosis of MS were identified using the
Medical Birth Registers between the years of 2005 and 2014 in Sweden and Finland. These
dates were selected because the PDR in Sweden began in 2005, so it would not be possible to
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(Prescribed Drug Register, National Patient
Register, and Swedish Medical Birth Register),
Karolinska Institute (MS register), and Statistics
Sweden (Total Population Register). In Finland, the
respective data are available from the National
Institute of Welfare and Health (Care Register for
Health Care, and Medical Birth Register, Register)
and from the Social Insurance Institute (National
Reimbursement Register and National
Prescription Register). Restrictions apply to the
availability of these data, which were used under
license for this study. The data supporting these
findings can be obtained by applying to the
respective data holders in Sweden and Finland. For
Sweden, data access queries can be sent to
Registerservice@socialstyrelsen.se for the PDR,
NPR, and MBR. For the MS register, data access
queries can be sent to the register co-ordinator,
anna.cunningham@ki.se. For the total population
register, data access queries can be sent to
scb@scb.se. For Finland, data access queries can
be sent to info@tfl.fi for the MBR and CRHC. For
the NRR and NPR, data access queries can be sent
to tilastot@kela.fi.
Funding: This study was funded by Bayer AG,
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Novartis Pharma AG, MS is employed by Merck
group, CP is employed by Biogen and KSW is
employed by Bayer AG. Novartis Pharma AG,
Merck group, Biogen and Bayer AG provided
support in the form of salaries for authors YG, MS,
CP, and KSW. The funders were not involved in
data collection or analysis, decision to publish, or
preparation of the manuscript beyond the
contributions of these authors, however they were
able to comment on study design in the initial
stages of the project. The specific roles of the
authors employed by the funders are articulated in
the ‘author contributions’ section. PV and PK are
employed by EPID research. EPID research
provided support in the form of salaries for authors
PV and PK, and were involved in data collection
and decision to publish, but were not involved in
data analysis or manuscript preparation beyond the
contributions of these authors. The specific roles of
the authors are articulated in the ‘author
contributions’ section.
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policy and the authors of this manuscript have the
following competing interests: This study was
funded by Bayer AG, Biogen Netherlands B.V.,
Merck KGaA, and Novartis Europharm Limited. SB
reports no personal conflict of interest, but works
for CPE which receives funding from third parties
including pharmaceutical companies. PV reports
identify prescriptions of IFN-beta prior to this date. The corresponding date was chosen as the
beginning of the study in Finland to ensure results were comparable. The end of the study was
31st December 2014, because at the time of the data application this was the most recently
available data. In Sweden, the mother’s diagnosis of MS was identified using the National
Patient Registers (NPR) (International Classification of Diseases tenth revision [ICD 10] code
G35), and the National Multiple Sclerosis Register (MSR). Informed consent is required for a
patient to be included in the MSR. Data for identification of exposure to IFN-beta and other
disease modifying treatments was retrieved from the Prescribed Drugs Register (PDR), which
records all collected prescriptions within Sweden and allows for identification of treatments
through the use of anatomical therapeutic chemical classification (ATC) system codes. The MS
Register was also used to identify when treatment had been initiated in hospital. In Finland, an
MS diagnosis was identified using the National Reimbursement Register, and the Care Register
for Health Care, and exposure to IFN-beta was retrieved from the Finnish PDR, using ATC
codes.
Only observations for which a birth height, birth weight, and birth head circumference
measurement had been recorded were included. All three measurements needed to be present
for the birth to be included in the study to ensure the same infants were being compared
throughout the analyses. All pregnancies to women with MS within Sweden and Finland
between 2005 and 2014 were included in this population based study.
Exposure and outcome
Exposure to IFN-beta was counted as having occurred if the individual collected a prescription
of IFN-beta during the exposure window, here defined as up to 6 months prior to the last men-
strual period (LMP) until the end of the pregnancy according to the PDR of Sweden or Fin-
land, or if a date of initiation for IFN-beta was recorded in the MSR in Sweden. It was assumed
that the woman would have been exposed to IFN-beta in the 3 months before LMP or later,
because the prescriptions are intended to last 3 months. Exposure to any MS DMD was also
identified using the same registers and exposure window (see S1 Table for the list of ATC
codes) aside from cladribine and mitoxantrone, for which exposure 6 months prior (purchase
9 months prior) to LMP was considered as exposed.
Within the MSR, exposure definitions are reliant on dates of treatment initiation and cessa-
tion. The accuracy of using such dates to determine exposure may be considered questionable.
Clinicians who only temporarily cease treatment due to the pregnancy would not necessarily
consider this a cessation of treatment. In these instances, date of cessation indicating the treat-
ment was stopped during pregnancy would go unrecorded. It is also possible that no cessation
date was recorded because the woman continued treatment during the exposure window. To
examine whether results changed when applying different exposure criteria from the MSR, a
sensitivity analysis identified all pregnancies with recorded treatment before the 6 months
prior to LMP exposure window but with no cessation date during the exposure window. This
analysis provides numbers exposed and mean values for each outcome, rather than comprising
the main definition due to the previously mentioned limitations. It was only possible to con-
duct this sensitivity analysis using Swedish data, since such information is not available in the
Finnish registers.
Pregnancies exposed to IFN-beta only were compared to pregnancies unexposed to any MS
DMD. Birth measurements for weight in grams, height in cm, and head circumference in cm
were used in a continuous form, and information was taken directly from the Medical Birth
Registers of Sweden and Finland.
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Statistical analysis
Linear regression using generalized estimating equations (GEEs) was undertaken in which the
mother’s ID was used as a cluster identifier which demarcates siblings. Maternal age at LMP,
gestational age in weeks, maternal smoking status, and within Sweden highest maternal educa-
tional attainment (separated into compulsory school or less, upper secondary, or higher educa-
tion) were considered to be possible confounders, and included in the adjusted models. Sex of
the newborn was also included in the model due to its association with birth measurements.
An analysis studying differently exposed siblings was also undertaken and included the same
confounders as covariates. Adjusting for maternal age at LMP meant birth order was consid-
ered in this model.
A sensitivity analysis which compared women exposed to any MS DMD (including but not
limited to IFN-beta) to women unexposed to any MS DMD was also undertaken to assess
whether the outcomes differed to when IFN-beta exposure only was studied.
Continuous measures which compare mean measurements between groups are the primary
outcomes used in this paper.
Ethics statement
In Finland, the study was given a positive opinion by the Helsinki University Hospital Ethics
Committee (Finland; 159/13/03/00/2016). Data permit approvals were granted by the National
Institute for Health and Welfare (Dnro THL/635/5.05.00/2016) and the Social Insurance Insti-
tution (Dnro 42/522/2016). In Sweden, the study was approved by the Regional Ethical Review
Board in Stockholm (Sweden; 2016/874-31/2). Data permit approvals were granted by
National Board of Health and Welfare (Dnr 23981/2016) and Swedish MS Registry (Dnr 53).
All individuals within Sweden and Finland are automatically included in administrative rec-
ords through entry into national registers at birth or immigration. Informed consent is not
gained for this. These databases are primarily administrative in nature, and are not set up with
research as the intended outcome, however they are commonly used for such purposes. The
datasets are held at the institutions listed in the data access statement, and were fully anon-
ymised by the holding institutions before delivery.
Results
In Sweden, 411 pregnancies were identified as exposed to IFN-beta during the exposure win-
dow for which all birth measurements were available, and 835 pregnancies were counted as
unexposed to any MS DMD. The corresponding numbers for Finland were 232 and 331,
respectively. Within Sweden, there were 1131, and within Finland 442 women with MS regis-
tered as having a pregnancy during the study time frame. In Sweden, there were 101 pregnan-
cies comprised of 50 sibling sets identified as being differently exposed to IFN-beta. The
corresponding numbers for Finland were 83 pregnancies comprised of 41 sibling sets. The
study population characteristics showed most women in Sweden had received higher educa-
tion (studying at university) as their highest educational attainment (data on education were
unavailable in Finland), and had a parity of 2 overall. When considering all pregnancies, the
unexposed cohort had on average a slightly older age at LMP relative to the exposed cohort in
Sweden, and in Finland the ages were very similar at LMP (Table 1). Gestational age at birth
was not significantly different among the exposed and unexposed cohorts, with mean gesta-
tional age of 39.7 weeks for the exposed and 39.5 weeks (p = 0.10) for the unexposed cohorts in
Sweden, and 39.4 weeks for the exposed and 39.5 weeks (p = 0.67) for the unexposed cohorts
in Finland. Births prior to 22 weeks are not recorded in the medical birth registers. Very early
Pre-natal interferon-beta exposure and birth measurements
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births under 32 weeks are rare. S1–S3 Figs show the distribution of birth measurements and
allow for identification of outliers.
In the adjusted analyses, infants prenatally exposed to IFN-beta were on average 28 grams
heavier (p = 0.17) in Sweden, and 50 grams lighter (p = 0.26) in Finland than those unexposed
(Table 2). For birth height, those exposed to IFN-beta were 0.01 cm longer (p = 0.95) in Swe-
den, and 0.02 cm shorter (p = 0.92) in Finland compared to those unexposed. For head cir-
cumference, those in Sweden had measurements 0.14 cm larger (p = 0.13) and in Finland 0.22
cm smaller (p = 0.15) relative to those unexposed (unadjusted analyses shown in Table 2,
adjusted analyses shown in Table 3).
Table 1. Exposed and unexposed cohort characteristics.
Sweden
All Differently exposed siblings
Exposed Unexposed Exposed Unexposed
Number of pregnancies 411 835 50 51
Mean (SE) Gestational age, weeks, 39.7 (0.1) 39.5 (0.1) 40.0 (0.2) 39.2 (0.3)
Mean (SE) Birth weight, grams 3465.9 (27.7) 3414.8 (19.4) 3475.5 (66.3) 3346.6 (81.7)
Mean (SE) Birth height, cm’s 50.1 (0.1) 50.0 (0.1) 50.3 (0.4) 49.7 (0.4)
Mean (SE) Head circumference, cm 35.0 (0.1) 35.0 (0.1) 35.0 (0.2) 34.7 (0.3)
Infant Sex
Male (%) 207 (50.4) 441 (52.8) 24 (48.0) 26 (51.0)
Female (%) 204 (49.6) 394 (47.2) 25 (52.0) 25 (49.0)
Mean (SE) maternal age, years 31.3 (0.2) 32.3 (0.2) 31.0 (0.6) 30.9 (0.5)
Maternal education
Compulsory school or less (%) 20 (4.9) 56 (6.7) 2 (4.0) 2 (3.9)
Upper secondary (%) 113 (27.5) 242 (30.0) 15 (30.0) 17 (33.3)
Higher education (%) 277 (67.4) 534 (64.0) 33 (66.0) 32 (62.8)
Missing data (%) 1 (0.2) 3 (0.4) 0 (0) 0 (0)
Smoking status
Smoker (%) 18 (4.4) 54 (6.5) 45 (90.0) 47 (92.2)
Nonsmoker (%) 378 (92.0) 740 (88.6) 3 (6.0) 0 (0)
Not known (%) 15 (3.7) 41 (4.9) 2 (4.0) 4 (7.8)
Finland
All Differently exposed siblings
Exposed Unexposed Exposed Unexposed
Number of pregnancies 232 331 41 42
Mean (SE) Gestational age, weeks, 39.4 (2.4) 39.5 (1.9) 39.4 (2.9) 40.0 (1.2)
Mean (SE) Birth weight, grams 3357.5 (628.3) 3410.4 (541.0) 3306.6 (649.2) 3508.4 (441.7)
Mean (SE) Birth height, cm’s 49.5 (3.1) 49.6 (2.5) 49.2 (3.8) 49.9 (1.9)
Mean (SE) Head circumference, cm 34.5 (2.2) 34.8 (1.7) 34.4 (2.6) 35.0 (1.4)
Infant Sex
Male 117 (50.4) 171 (51.7) 18 (43.9) 18 (43.9)
Female 115 (49.6) 160 (48.3) 23 (56.1) 24 (57.1)
Mean (SE) maternal age, years 30.0 (4.2) 30.6 (4.5) 30.0 (4.2) 30.6 (4.5)
Maternal education Not available Not available Not available Not available
Smoking status
Smoker (%) 33 (14.2) 49 (14.8) 2 (4.9) 3 (7.1)
Nonsmoker (%) 195 (84.1) 277 (83.7) 39 (95.1) 39 (92.9)
Not known (%) 4 (1.7) 5 (1.5) 0 (0) 0 (0)
https://doi.org/10.1371/journal.pone.0227120.t001
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Analysis of groups of siblings in which at least one sibling was exposed, and at least one sib-
ling was unexposed was undertaken (see Tables 2 and 3). Overall, differences between siblings
exposed and siblings unexposed to IFN-beta during pregnancy were minimal, and not statisti-
cally significant. The same was true when considering exposure to any MS DMD, relative to
non-exposure to MS DMD (see S3–S5 Tables).
Discussion
Infants born to women with MS exposed to IFN-beta during pregnancy did not show evidence
of decreased intrauterine growth relative to infants born to MS women unexposed to IFN-beta
during pregnancy. There were also no differences in mean gestational age at birth. No differ-
ences were found when comparing infants prenatally exposed to any MS DMD, relative to
infants not exposed to MS DMD. This confirms evidence from some past studies which report
no adverse effects for infants prenatally exposed to IFN-beta[5, 7, 10], and refutes the findings
of other studies which have found IFN-beta is associated with birth measurement[11].
Birth measurements which are substantially below average have been reported to be associ-
ated with a number of adverse health outcomes, including behavioural difficulties such as
ADHD[12], and other health conditions including coronary heart disease and diabetes[13,
14], although the extent to which these effects are confounded by social or genetic factors is
incompletely understood[15]. The increased risks of adverse outcomes later in life highlights
the importance of studying such measures.
Gestational age is one of the most critical factors determining birth measurements[16],
with expected foetal weight gain of 24–26 grams per day in the third trimester for low risk
pregnancies[17]. Gestational ages at birth were comparable across exposure groups, and
maternal ages at LMP, indicating exposure to IFN-beta does not result in earlier gestational
Table 2. GEE’s unadjusted- differences in mean weight, height, and head circumference between exposed and unexposed cohorts.
Unadjusted
Weight P-value Height P-value Head circumference P-value
Sweden
Overall 51.1 (37.4) 0.17 0.12 (0.2) 0.48 0.20 (0.1) 0.08
Differently exposed siblings 128.8 (110.0) 0.24 0.53 (0.5) 0.27 0.31 (0.3) 0.34
Finland
Overall -52.8 (59.6) 0.38 -0.10 (0.3) 0.74 -0.26 (0.2) 0.21
Differently exposed siblings -198.2 (126.7) 0.12 -0.71 (0.8) 0.36 -0.57 (0.5) 0.3
https://doi.org/10.1371/journal.pone.0227120.t002
Table 3. GEE’s adjusted- differences in mean weight, height, and head circumference between exposed and unexposed cohorts.
Adjusted�
Weight P-value Height P-value Head circumference P-value
Sweden
Overall 27.8 (20.1) 0.34 0.01 (0.1) 0.95 0.14 (0.1) 0.13
Differently exposed siblings -21.6 (77.1) 0.78 -0.10 (0.4) 0.78 -0.05 (0.3) 0.85
Finland
Overall -50.3 (45.1) 0.27 -0.02 (0.2) 0.92 -0.21 (0.2) 0.15
Differently exposed siblings -83.6 (79.8) 0.30 0.07 (0.4) 0.85 -0.008 (0.3) 0.98
�Adjusted for gestational age, sex of the newborn, smoking status of the mother, and maternal age at LMP
https://doi.org/10.1371/journal.pone.0227120.t003
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age at birth, and will therefore not have an impact on birth measurements through this
mechanism.
One explanation as to why IFN-beta may not be influencing birth measurements or gesta-
tional age could be due to its pharmacokinetic characteristics. The placental barrier is a semi-
permeable tissue which separates foetal and maternal blood, and is only permeable for
substances with a low molecular weight (between 600 and 800 Dalton)[18]. IFN-beta is catego-
rized as a polypeptide with a molecular weight of 22.kDa (kiloDalton) for IFN-beta 1a and
18.5kDa for IFN-beta 1b[19], which is too large to permeate the placental barrier. The likeli-
hood of IFN-beta therefore being able to directly affect the development of the foetus through
permeation of foetal blood is unlikely, and suggests the lack of an effect of IFN-beta on foetal
growth measurements is biologically plausible.
The maternal identification numbers included in our data allowed for observation of spe-
cific sets of siblings. This was particularly useful, as it enabled us to consider the effect of expo-
sure to IFN-beta on an individual, relative to their unexposed sibling or siblings. In contrast to
regular population analysis, sibling analysis controls by design for unmeasured shared familial
(genetic and environmental) factors. Differences between the sibling exposure groups for all
included birth measurements were not statistically significant for either Sweden or Finland.
Younger women are more likely to be of lower parity, and to have smaller mean birth mea-
surements for their offspring[20]. Previous studies have indicated the effect of young maternal
age on low birth height and weight measurements does not persist when behavioural, biologi-
cal, and socioeconomic confounders have been controlled for[21, 22], indicating that maternal
age may primarily be a confounder. Our study indicated the age at LMP for the pregnancies
exposed to IFN-beta was on average lower than the age at LMP for the pregnancies unexposed
to any MS DMD. This has the potential to influence birth measurements through potentially
unmeasured confounders[23], even though maternal age at LMP itself has been included in
the adjusted models.
A strength of this register study was our ability to include all women with MS who had a
pregnancy that ended with a birth in both Sweden and Finland during the study period. Previ-
ous studies have relied on samples which can be self-selecting, and have reduced power due to
smaller numbers enrolled than is possible using register data[24]. Inclusion of a population of
pregnant women, with information available for all pregnancies to a particular patient group,
removes the possibility of selection bias through for example over-recruitment of low- or high-
risk pregnancies, improving the reliability of the results.
Potential limitations of the study should also be considered. It was not possible to know
whether exposure identified using the Prescribed Drugs Register resulted in an exposed preg-
nancy, because we cannot be certain the treatment was taken by the mother. Only data which
stated the drug had been dispensed was available for prescriptions, with the assumption then
made that the treatment was taken as instructed. Previous studies into different treatments
have indicated that pregnant women are less likely to adhere to treatment than other patient
groups[25, 26], which increases the likelihood that dispensation does not necessarily equate to
exposure. Only pregnancies for which information was recorded for all three measurements
(weight, height, and head circumference at birth) were included in the study. If missingness is
differential by exposure status, bias may be induced. We were limited in the variables we were
able to adjust for, due to limited information being provided in registers. For example, poten-
tially informative data on diet and physical activity are not available. A live birth had to have
occurred for inclusion in the study population. The Medical Birth Registers of Sweden and
Finland record births occurring at 22 weeks or later of pregnancy. Elective terminations are
additionally not identifiable in the Swedish data. If the rates of elective termination and spon-
taneous abortion differ by exposure group, there is the potential for bias to be induced.
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PLOS ONE | https://doi.org/10.1371/journal.pone.0227120 December 30, 2019 7 / 10
In summary, the evidence from this large population based study indicate no association
between IFN-beta exposure and fetal growth or gestational age among infants of women with
MS.
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